Our Team


profile picture

Geoff Ginsburg, M.D., Ph.D., G2MC Co-Chair and President

Dr. Ginsburg is the founding director of the Center for Applied Genomics & Precision Medicine at the Duke University Medical Center and of MEDx, a partnership between the Schools of Medicine and Engineering to spark and translate innovation. His research addresses the challenges for translating genomic information into medical practice and the integration of precision medicine into healthcare.

Besides G2MC, Dr. Ginsburg’s genomic medicine implementation projects include:

Implementing GeNomics In pracTicE (IGNITE)

National Academies of Medicine Roundtable on Genomics and Precision Health

See Full Bio

profile picture

George P. Patrinos, Ph.D., G2MC Co-Chair

Dr. Patrinos group is internationally renowned for his involvement in the field of pharmacogenomics research. His research includes discovery work and addresses the issue of clinical implementation of pharmacogenomics in an holistic manner, including wet- and dry-lab, as well as public health genomics approaches. Dr. Patrinos has also a keen interest in the clinical implementation of genomic medicine in resource-limited environments.

Besides G2MC, Dr. Patrinos’s Genomic Medicine Implementation Projects include:

Genomic Medicine Alliance (GMA)

Ubiquitous Pharmacogenomics (U-PGx)

See Full Bio

profile picture

Robyn Ward, M.B.B.S., Ph.D., FRACP, G2MC Co-Chair

Executive Dean, Faculty of Medicine, The University of Sydney, Australia

Professor Ward is an academic leader, cancer researcher and medical oncologist. She is a member of the Pharmaceutical Benefits Advisory Committee (PBAC), chairs the Commonwealth Medical Services Advisory Committee (MSAC), and serves on the Council and Executive of the Australian Academy of Health and Medical Sciences. Professor Ward was previously with the University of Queensland, where she was Deputy Vice-Chancellor (Research) and Executive Dean (Acting) of the Faculty of Medicine. In 2013 she was made Member of the Order of Australia (AM) for significant service to medical research and patient care in the field of oncology.

Besides G2MC, Prof. Ward’s genomic medicine implementation projects include:

Queensland Genomics Health Alliance

Australian Genomics Health Alliance

See Full Bio

Executive Team

profile picture

Teri Manolio, M.D., Ph.D.

Dr. Manolio is a physician an epidemiologist at the NIH and Walter Reed National Military Medical Centre. She joined NHGRI in 2005 to lead efforts in applying genomic technologies to population research. She has authored over 270 research reports and has research interests in genome-wide association studies of complex diseases, ethnic differences in disease risk, and incorporating genomic findings into clinical care.

Besides G2MC, Dr. Manolio’s genomic medicine implementation projects include:

Electronic Medical Records and Genetics (eMERGE) Network

NHGRI Genome-Wide Association Catalogue

Clinical Genome (ClinGen) Resource

See Full Bio

profile picture

Prof. Vajira H. W. Dissanayake MBBS, PhD, FNASSL

Chair Professor Anatomy; Director, Human Genetics Unit

Chairperson, Specialty Board in Biomedical Informatics, University of Colombo, Sri Lanka

Dr. Dissanayake is the Director of the Human Genetics Unit (HGU), at the Faculty of Medicine, University of Colombo, Sri Lanka and the Founder of the Asiri Center for Genomic and Regenerative Medicine at the Asiri Groups of Hospitals in Colombo. He spearheads various initiatives in Genetics, Genomics and Biomedical Informatics in Sri Lanka. He has authored over 80 research papers, including Implementation of Genomic Medicine in Sri Lanka: Initial Experience and Challenges. Prof. Dissanayake is the current President of the Commonwealth Medical Association, which includes representation from over 50 countries.

See Full Bio

profile picture

Alan Shuldiner, M.D.

Vice President, Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., USA

John Whitehurst Professor of Medicine, University of Maryland School of Medicine, USA

Dr. Shuldiner founded and directs the Discovery Research Investigating Founder Population Traits (DRIFT) Program at the Regeneron Genetics Center. Their goals are to (i) catalogue population-specific allelic architecture; (ii) understand the biological and functional consequences of specific mutations identified; and (iii) share and establish best practice approaches to relieve disease burden in these populations. In his part-time role at the University of Maryland, Dr. Shuldiner is Associate Dean and Director of the Program for Personalized and Genomic Medicine whose mission is to is to advance discovery in genomics and other “omic” sciences. Dr. Shuldiner’s research applies high-throughput sequencing technologies to better understand human health and disease toward the identification and development of novel therapeutic targets and preventive therapies for diseases of unmet need. He also works to implement evidence-based genomic medicine and pharmacogenetics into patient care.

See Full Bio

Steering Committee

profile picture

Marc Abramowicz, Ph.D. M.D.

Professor, Université Libre de Bruxelles, Belgium

Dr. Abramowicz is a clinical geneticist, Professor of medical genetics at the Université Libre de Bruxelles, Belgium, and has been heading the Medical Genetics dept of University Hospital Erasme, Brussels, Belgium, since 2009. As of Dec 1st, 2017, Marc Abramowicz is a Professor at the University of Geneva and Head of the dept of Medical Genetics of the Hopitaux Universitaires (HUG), Geneva, Switzerland. Dr Abramowicz has authored more than 100 research papers relating to genetics or genomics

Besides G2MC, Dr. Abramowicz’s genomic medicine implementation projects include :

Belgian Medical Genomics Initiative

National College of Human Genetics

profile picture

Fahd Al-Mulla, M.B.Ch.B, PCTM, FRCP, Ph.D.

Dr. Al-Mulla is professor of molecular pathology and genomic medicine at Kuwait University and adjunct Faculty at Marshall University, Joan C. Edwards School of Medicine USA. Fahd is the founding director of Genatak, a center of genomic medicine, which aims at delivering state-of-the-art genomic services to the public and health services in the Middle East. His research addresses the challenges for translating genomic information into cancer diagnosis, prognosis and precision treatment.

Besides G2MC, Dr. Al-Mulla’s Genomic Medicine Implementation Projects include:

Implementing genomic medicine practices in familial breast, colorectal and prostate cancer.

Establishing the Arabian genome map. Collaborating with pharmaceutical industry for establishing novel treatments for cancer and metastasis.

See Full Bio

profile picture

Wasun Chantratita, Ph.D.

Chief of Virology and Molecular Microbiology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand

Dr. Chatratita has carried out both research and routine molecular diagnosis in virology at the Virology Laboratory and Medical Genomic Center at Ramathibodi hospital, Mahidol University since 2001. So far, more than 50,000 of various type of clinical species nationwide have been sent to his unit annually for molecular viral diagnosis. In 2003, Dr. Chantratita was chosen by Thailand Center of Excellence for Life Sciences (TCELS) to run a government prototype project. In 2013, Dr. Chantratita and his team applied their knowledge and experience gained from pharmacogenomics project to establish the Center of Excellence in Medical Genomics Center, which is supported by TCELS and Ramathibodi Hospital.

profile picture

Peter Goodhand

Goodhand played a key role in the creation of the Global Alliance for Genomics and Health (GA4GH) and was appointed as its founding Executive Director in 2014. He was appointed the President of OICR in March, 2017 after spending a year as the Interim President. Previously, Goodhand was the President and CEO of the Canadian Cancer Society. Before joining the charitable sector, he had a 20 year career in the global medical technology industry, including strategic leadership roles with multinational healthcare companies such as American Cyanamid and Johnson & Johnson and as the founding Managing Director of the Health Technology Exchange (HTX).

See Full Bio

profile picture

Bruce Korf

Wayne H. and Sara Crews Finley Chair in Medical Genetics, Professor of Genetics, University of Alabama at Birmingham, USA

Chief Genomics Officer, UAB Medicine, USA

Associate Director for Rare Diseases, Hugh Kaul Personalized Medicine Institute, USA

Co-Director of the UAB-HudsonAlpha Center for Genomic Medicine, USA

Bruce Korf is a medical geneticist, pediatrician, and child neurologist, certified by the American Board of Medical Genetics (clinical genetics, clinical cytogenetics, clinical molecular genetics), American Board of Pediatrics, and American Board of Psychiatry and Neurology (child neurology). Dr. Korf is past president of the Association of Professors of Human and Medical Genetics, past president of the American College of Medical Genetics and Genomics, and current president of the ACMG Foundation for Genetic and Genomic Medicine. He has served on the Board of Scientific Counselors of the National Cancer Institute and the National Human Genome Research Institute at the NIH. He chairs the Medical Advisory Committee of the Children’s Tumor Foundation and serves on the CTF Board of Directors.

Besides G2MC, Dr. Korf’s Genomic Medicine Implementation Projects include:

CSER2: SouthSeq: Clinical Sequencing Among Communities in the Deep South

Southern All of Us Network

T32 Genomic Medicine

See Full Bio

profile picture

Gad Rennert, M.D., Ph.D.

Director, Clalit National Cancer Control Center and National Personalized Medicine Program, Israel

Professor and Chairman, Department of Community Medicine and Epidemiology, Carmel Medical Center and B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Israel

Dr. Rennert’s research interests are in molecular/genetic cancer epidemiology, cancer prevention and screening, and in molecular or personalized targeted medicine. Cancer chemoprevention studies are another focus of his scientific work. He is currently studying and coordinating the cancer screening activities on a national level in Israel and studying unique founder mutations leading to cancer through the Familial Cancer Consultation Service which cares for thousands of mutation carriers.

Dr. Rennert’s work involves a deep epidemiological evaluation of more than 40,000 study participants combined with massive genetic testing using RT-PCR, Sanger sequencing, deep next-generation sequencing, microarray testing, multi-gene expression panels studies, Onco-chip multi-SNP panel, whole exome analysis and other laboratory methods.

profile picture

Gabriela Repetto

Dr Repetto is a Clinical Geneticist and Director of the Center for Genetics and Genomics at Facultad de Medicina Clinica Alemana Universidad del Desarrollo in Santiago, Chile, a leading clinical, teaching and research interdisciplinary center in Medical Genetics and Genomics. She is part of the new Institute for Science and Innovations in Medicine (ICIM) at Universidad del Desarrollo. Her research interests include rare and undiagnosed genetic disorders, and advancing the development and incorporation of Genomic Medicine in South America.

Besides G2MC, Dr. Repetto´s genomic medicine implementation projects include:

Chilean Rare Diseases Program

See Full Bio

profile picture

John Wong, Ph.D. M.B.B.S.

Senior Vice President, Health Affairs, Chief Executive and Isabel Chan Professor in Medical Services, National University of Singapore, Singapore

Prof. Wong is actively involved in the development of Biomedical Sciences as a key pillar of Singapore’s economy, as well as the development of Singapore’s first academic health system linking the National University Hospital and National University of Singapore’s (NUS) medical, public health, dental, and nursing schools under one unified governance. Prof Wong represents Singapore in the M8 Alliance of Academic Health Centers and the Association of Academic Health Centers – International. He jointly founded the Cancer Therapeutics Research Group, a multinational consortium of nine academic institutions. He was awarded the Public Administration Medal (Silver) in 2005 and the National Outstanding Clinician Award in 2009. He also received the SASS Foundation award in 2010.. In 2013, he received the Outstanding Service Award from NUS.

Besides G2MC, Dr. Wonkam’s genomic medicine implementation projects include:

World Economic Forum Global Agenda Council on Personalized and Precision Medicine

See Full Bio

profile picture

Ambroise Wonkam, M.D. Ph.D.

Dr. Wonkam completed his thesis in Cell Biology at the Department of Morphology, University of Geneva and was awarded the 2003 Denber-Pinard prize for the best thesis from the Faculty of Medicine, University of Geneva. He has practiced medical genetics in both European and African contexts. Dr. Wonkam’s interests are reflected in more than 100 peer-reviewed publications, which are in molecular, clinical, educational and ethical aspects of medical genetics. He was awarded the UK Clinical Genetics International Fellowship from the British Society of Genetics Medicine in 2014.

Besides G2MC, Dr. Wonkam’s genomic medicine implementation projects include:

African Society of Human Genetics

International Federation of Human Genetics Societies

HUGO council

See Full Bio

profile picture

Grant Wood

Grant Wood has worked with Intermountain Healthcare’s Clinical Genetics group for over 12 years. He is responsible for creating computer systems that will support healthcare providers in delivering genetics-based clinical care, which include applications that collect family health history and genetic test result data to enable advanced clinical decision support.

Wood participates in a number of projects relating to family health history and clinical genetics. He is a contributor to the Global Alliance for Genomics and Health, is a co-chair of the pilot workgroup for the DIGITizE Action to get coded genetic data from the lab to electronic health records, is a co-chair of the WEDI Genomics workgroup.